#London #United Kingdom #Bone Regeneration #Enamel Technology #Eterna Regeneratives

Eterna Regeneratives Secures $4M Funding for Revolutionizing Dental Care

In a significant boost for dental and tissue repair technologies, UK-based startup Eterna Regeneratives has successfully closed a seed funding round, raising $4 million. This investment was led by Hoxton Ventures and The Venture Collective (TVC), and it aims to develop a groundbreaking platform that focuses on the regeneration of tooth enamel and bone.

Co-founded in 2024 by Khaled Eissa and Dr. Sherif Elsharkawy, the company emerged from King's College London and has garnered attention for its innovative approach to dental care. Eterna's technology, which leverages a proprietary keratin-based material, could potentially transform how dental health issues are treated, particularly in the colossal $43 billion global oral care market.

The Power of Keratin

Eterna's journey began when research demonstrated the capability of a keratin substance—protein abundantly found in human hair and skin—to regrow damaged tooth enamel. The team, including Dr. Elsharkawy and his PhD student, Dr. Sara Gamea, caught the interest of major media outlets such as the BBC and the Washington Post, highlighting the promise of keratin for dental regeneration even before a commercial product was developed.

Tooth enamel is unique in that it does not naturally regenerate once it has been lost. This loss can lead to various dental issues like hypersensitivity and cavities. Current solutions, like fluoride treatments and resin fillings, only offer temporary fixes or minor enhancements of existing enamel. Fluoride helps strengthen the enamel, whereas resin merely fills it but doesn’t restore the lost structure.

Eterna seeks to change this narrative. The company's keratin-based formula integrates seamlessly into existing oral care products, offering a cost-effective and long-lasting solution for enamel regeneration. Preliminary tests have shown promising results where treated tooth samples exhibited new layers similar to natural enamel, restoring hardness and strength, and even showing effectiveness against decay.

A Paradigm Shift in Dental Care

Khaled Eissa, co-founder and CEO of Eterna, emphasized their mission: "The only way to truly heal the human body is to help it heal itself. We wanted to create a product that is readily available, scalable, and has the potential to deliver long-term results." With the new funding, Eterna plans to accelerate its transition from lab research to real-world applications, focusing on bringing their product directly to consumers.

Hussein Kanji, a partner at Hoxton Ventures, spoke highly of Eterna's potential, stating that their technology could significantly change the landscape of oral care, shifting from merely managing enamel loss to actively repairing it. The second phase of Eterna's development will apply the same keratin technology to bone regeneration, offering hope for more effective treatments in orthopedic care as well.

Future Directions

Eterna Regeneratives is not stopping with enamel repair. Their vision includes exploring further intellectual property developments, expanding their research capabilities, and fostering partnerships within the healthcare industry. The company is on a solid path to deliver its first commercial product shortly.

As Eterna Regeneratives continues to innovate in the field of biotechnologies, the startup's commitment to helping the body heal itself could pave the way for new standards in health and care. Integrated into existing products, their scientific breakthroughs may eventually be accessible to millions worldwide, transforming how both dental and bone health challenges are addressed.

Eterna Regeneratives is more than just a startup; it's a pioneer in the quest to rebuild and restore the body's essential structures, enhancing health outcomes for consumers globally. Their upcoming advancements promise to bring a bright future not only for dental care but also for broader applications in tissue and bone regeneration.